Unexpected Synergy Reveals New Therapeutic Strategy in SCLC

Benjamin J. Drapkin, Anna F. Farago

Research output: Contribution to journalShort surveypeer-review

11 Scopus citations


DNA damage repair (DDR) inhibition and immune checkpoint blockade (ICB) have each individually shown modest clinical activity in small cell lung cancer (SCLC). Recently, Sen and colleagues (Cancer Discov. 2019;https://doi.org/10.1158/2159-8290.CD-18-1020) demonstrated that DDR inhibition can activate the stimulator of interferon genes (STING) innate immune pathway, providing strong rationale for combining DDR inhibition and ICB to treat SCLC.

Original languageEnglish (US)
Pages (from-to)295-297
Number of pages3
JournalTrends in Pharmacological Sciences
Issue number5
StatePublished - May 2019
Externally publishedYes


  • checkpoint kinase 1 inhibitor
  • immune checkpoint blockade
  • PARP inhibitor
  • PD-1
  • PD-L1
  • SCLC

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology


Dive into the research topics of 'Unexpected Synergy Reveals New Therapeutic Strategy in SCLC'. Together they form a unique fingerprint.

Cite this